Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.50 |
| ▸ | CA2 | P00918 | 17/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA5A | P35218 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613294 | 0.94 | CA1 (0.55) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3612871 | 0.94 | CA1 (0.55) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3608507 | 0.90 | CA1 (0.53) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL13119753 | 0.87 | CA1 (0.48) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3596074 | 0.87 | NPC1 (0.58) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3603208 | 0.85 | CA1 (0.54) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3603224 | 0.84 | NPC1 (0.47) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL4517904 | 0.83 | CA1 (0.49) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3160315 | 0.83 | CA1 (0.61) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3610354 | 0.83 | NPC1 (0.54) | NPC1RAB9AL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | claimed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | CA1 4588/4885CA2 4128/4885CA12 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.